Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

BACKGROUND AND PURPOSE: Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is known about long‐term therapy. METHODS: This study was an open‐label, 5‐year treatment phase following a 12‐week, double‐bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Messoud, Goadsby, Peter J., Reuter, Uwe, Silberstein, Stephen, Dodick, David W., Xue, Fei, Zhang, Feng, Paiva da Silva Lima, Gabriel, Cheng, Sunfa, Mikol, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Headache
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248354/
https://www.ncbi.nlm.nih.gov/pubmed/33400330
http://dx.doi.org/10.1111/ene.14715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248354/
https://www.ncbi.nlm.nih.gov/pubmed/33400330
http://dx.doi.org/10.1111/ene.14715

Ejemplares similares